Interim results for the six months ended 30 June 2025
Interim results for the six months ended 30 June 2025
Back to News
Shield Therapeutics: Interim results for the six months ended 30 June 2025
Watch Shield Therapeutics' latest callShield Therapeutics (LSE:STX) — Q4 2025 Trading Update · Replay · Jan 22Read the transcript of Shield Therapeutics (LSE:STX) — Q4 2025 Trading UpdateShield Therapeutics PLC on 6ix
Story so far
Earlier from Shield Therapeutics
- Q2 2025 Trading Update
- Result of AGM
- Annual Report and Accounts for the year ended 2024
- Audited results for the year ended 31 Dec 2024
- Licence Agreement in Japan for ACCRUFeR®
Later from Shield Therapeutics
- Data published -European Journal of Heart Failure
- Interim results for the six months ended 30 Jun 25
- ACCRUFeR® assigned Priority Review in US by FDA
- £1.5 million placing supporting growth of ACCRUFeR
- Positive efficacy and tolerance in pediatric trial
Follow Shield Therapeutics into a list and get an email when it puts out news.
Follow Shield Therapeutics